drugset / Trial / NCT01220232

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects

NCT01220232

Phase 1 Completed 14 enrolled Pfizer ViiV Healthcare · collab
Non-randomizedCrossoverOpen-labelTreatment

Summary

This will be an open-label, fixed-sequence, multiple dose crossover study in 14 healthy male and/or female subjects, to estimate the effect of steady state lersivirine on the steady state pharmacokinetics of abacavir/lamivudine.

Timeline

Start
2010-11
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified 600 mg
Subject Lamivudine Other / unclassified 300 mg
Subject Lersivirine Small molecule 750 mg

Indications

No indication recorded.